RxDoctor Payments Data

Collese McKee

Family · South Bend, INNPI 1730810078

Payments from drug & device makers

$1,525in general payments, 2019–2025

Across 80 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$360
  • Novo Nordisk$203
  • Pfizer$169
  • Lilly USA, LLC$95
  • Lundbeck LLC$93
  • AstraZeneca$85
  • plus $520 from 14 others

What the payments were for

  • Food & beverage$1,50699%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,525 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$53,010
Medicare patients
156
Services billed
922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide54$62,673
OzempicSemaglutide56$61,896
EliquisApixaban38$36,111
JardianceEmpagliflozin32$35,235
RybelsusSemaglutide17$16,066
FarxigaDapagliflozin Propanediol11$9,898
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,245
Breo ElliptaFluticasone/Vilanterol24$9,242
MyrbetriqMirabegron13$5,944
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,854
Levothyroxine Sodium213$1,875
SynthroidLevothyroxine Sodium34$1,632
Atorvastatin Calcium201$1,527
Albuterol Sulfate HfaAlbuterol Sulfate74$1,389
Duloxetine Hcl51$1,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$203$77,96273 claims
Lilly USA, LLCMounjaro$95$62,67354 claims
PfizerEliquis$169$36,11138 claims
Boehringer IngelheimJardiance$55$35,23532 claims
GSKTrelegy Ellipta, Breo Ellipta$23$18,48736 claims
AstraZenecaFarxiga$85$9,89811 claims
AbbVieSynthroid$360$1,63234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →